We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+12.64%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$891M
(+9.3%)
Cap. Flow
-$92.8M
Cap. Flow
% of AUM
-0.89%
Top 10 Holdings %
Top 10 Hldgs %
36.27%
Holding
147
New
14
Increased
53
Reduced
21
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$98.5M |
| 2 |
SIEN
Sientra, Inc.
SIEN
|
+$54.3M |
| 3 |
Gilead Sciences
GILD
|
+$50.4M |
| 4 |
MGLN
Magellan Health Services, Inc.
MGLN
|
+$47.6M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$42.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CFN
CAREFUSION CORPORATION
CFN
|
+$215M |
| 2 |
Agilent Technologies
A
|
+$79M |
| 3 |
Arrowhead Research
ARWR
|
+$76.5M |
| 4 |
STJ
St Jude Medical
STJ
|
+$54.8M |
| 5 |
QGENF
QIAGEN NV
QGENF
|
+$38.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.82% |
| 2 | Financials | 0.08% |
| 3 | Technology | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
76
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $19.1M | 0.18% |
+156,100
| New | +$15.8M |
|
77
Jazz Pharmaceuticals
JAZZ
$16.1B
| $18.8M | 0.18% |
115,000
| – | – |
|
78
Elevance Health
ELV
$83.7B
| $17.4M | 0.17% |
138,800
+20,300
| +17% | +$2.51M |
|
79
Xencor
XNCR
$1.48B
| $16.8M | 0.16% |
1,046,000
+207,300
| +25% | +$2.4M |
|
|
MRGE
80
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
| $16.5M | 0.16% |
4,628,500
| – | – |
|
81
Pacira BioSciences
PCRX
$1.05B
| $15.6M | 0.15% |
176,000
-61,900
| -26% | -$5.86M |
|
|
SAGE
82
DELISTED
Sage Therapeutics
SAGE
| $15.1M | 0.14% |
412,335
-125,000
| -23% | -$4.66M |
|
83
CALL
Bristol-Myers Squibb
BMY
$130B
| $14.8M | 0.14% |
250,000
-50,000
| -17% | -$2.82M |
|
|
SVA
84
DELISTED
Sinovac Biotech, Ltd
SVA
| $14.8M | 0.14% |
2,821,500
| – | – |
|
|
ROKA
85
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
| $14.2M | 0.14% |
322,043
| – | – |
|
|
HZNP
86
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $13.9M | 0.13% |
1,075,000
+179,000
| +20% | +$2.24M |
|
|
STJ
87
DELISTED
St Jude Medical
STJ
| $11.3M | 0.11% |
173,000
-850,600
| -83% | -$54.8M |
|
|
SHPG
88
CALL
DELISTED
Shire pic
SHPG
| $10.6M | 0.1% |
50,000
-900,000
| -95% | -$191M |
|
|
LITS
89
Lite Strategy Inc
LITS
$33M
| $10.4M | 0.1% |
121,225
+25,000
| +26% | +$3.29M |
|
|
PTX
90
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
| $10.1M | 0.1% |
107,300
| – | – |
|
|
AGEN
91
Agenus
AGEN
$275M
| $9.69M | 0.09% |
124,394
-58,318
| -32% | -$3.59M |
|
92
MiMedx Group
MDXG
$649M
| $9.65M | 0.09% |
836,800
+41,400
| +5% | +$409K |
|
93
Abbott
ABT
$187B
| $9.5M | 0.09% |
211,000
+31,000
| +17% | +$1.35M |
|
|
SLXP
94
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $9.43M | 0.09% |
82,000
| – | – |
|
|
AEGR
95
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
| $8.38M | 0.08% |
+400,000
| New | +$10.1M |
|
|
AET
96
DELISTED
Aetna Inc
AET
| $8.35M | 0.08% |
94,000
+14,000
| +18% | +$1.17M |
|
|
ALIM
97
DELISTED
Alimera Sciences
ALIM
| $8.31M | 0.08% |
100,000
| – | – |
|
|
RDHL
98
Redhill Biopharma
RDHL
$4.44M
| $8.07M | 0.08% |
606
| – | – |
|
|
GEVA
99
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $7.22M | 0.07% |
77,800
-33,300
| -30% | -$2.63M |
|
|
XOMA
100
DELISTED
Xoma
XOMA
| $7.18M | 0.07% |
100,000
-21,850
| -18% | -$1.87M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q4 2014 Portfolio in Review
As of Q4 2014, OrbiMed held 147 positions worth $10.5B, up 9.3% from $9.57B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
OrbiMed's Q4 2014 filing shows 14 new, 53 increased, 21 reduced and 16 closed positions. Its largest new stake was Sientra, Inc.: 318,531 shares worth $53.5M. The largest sale was CAREFUSION CORPORATION, an estimated $215M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier, followed by Financials and Technology.
- OrbiMed's largest Q4 2014 buy was Sientra, Inc.: 318,531 shares worth $53.5M.
- OrbiMed added most to Biogen in Q4 2014, an estimated $98.5M increase.
- OrbiMed's biggest Q4 2014 reduction was Agilent Technologies, cutting an estimated $79M.
- OrbiMed fully exited CAREFUSION CORPORATION in Q4 2014, selling an estimated $215M.
- OrbiMed's ten largest holdings make up 36% of its $10.5B portfolio in Q4 2014.
- OrbiMed opened 14 new positions and closed 16 in Q4 2014.
- OrbiMed's portfolio value rose 9.3% quarter-over-quarter to $10.5B.
Based on OrbiMed's 13F filing for Q4 2014, filed 13 Feb 2015.